2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation.

@article{Duncan20122MethoxyestradiolIE,
  title={2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation.},
  author={Gordon S. Duncan and Dirk H{\"a}ussinger Brenner and Michael W. Tusche and Anne Br{\"u}stle and Christiane B. Knobbe and Andrew James Elia and Thomas Mock and Mark R. Bray and Peter Heinrich Krammer and Tak W Mak},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2012},
  volume={109 51},
  pages={21034-9}
}
The endogenous metabolite of estradiol, 2-Methoxyestradiol (2ME2), is an antimitotic and antiangiogenic cancer drug candidate that also exhibits disease-modifying activity in animal models of rheumatoid arthritis (RA). We found that 2ME2 dramatically suppresses development of mouse experimental autoimmune encephalomyelitis (EAE), a rodent model of multiple sclerosis (MS). 2ME2 inhibits in vitro lymphocyte activation, cytokine production, and proliferation in a dose-dependent fashion. 2ME2… CONTINUE READING